Mesenchymal stem cells stimulate protective genetic reprogramming of injured cardiac ventricular myocytes
A 2011 laboratory study of how human mesenchymal stem cells interact with injured heart-muscle cells
Heart muscle cells — cardiomyocytes — can be injured after a heart attack, during inflammation, or in heart failure. This page summarizes a peer-reviewed laboratory study of how human mesenchymal stem cells (hMSCs) interact with injured ventricular myocytes. It is a cell-culture paper, not a clinical trial in people, and it does not measure symptoms, survival, or heart-pump function in patients.
The study
In 2011, Terry B. Rogers, Shibani Pati, and colleagues published “Mesenchymal stem cells stimulate protective genetic reprogramming of injured cardiac ventricular myocytes” in the Journal of Molecular and Cellular Cardiology (volume 50, issue 2, pages 346–356). The paper appeared online on 15 September 2010. The corresponding author was based at the Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine. The article is indexed in PubMed as PMID 20837021 and is available via PubMed and doi:10.1016/j.yjmcc.2010.09.001.
What was studied, and how
The researchers asked whether hMSCs can help damaged ventricular heart-muscle cells directly. They used cultures of neonatal mouse ventricular cardiac myocytes. Injury was produced with two separate acute stress protocols: incubation with the bacterial endotoxin lipopolysaccharide (LPS), or with the inflammatory cytokine interleukin-1β (IL-1β).
Myocyte injury was judged by intracellular calcium signaling. The cells were loaded with the calcium dye fluo-3 and imaged at high temporal resolution with fluorescent microscopy. After LPS or IL-1β, the cells showed chaotic calcium handling. The authors quantified that injury as a 3- to 5-fold increase in spontaneous calcium transients.
Findings
Antibody neutralization experiments indicated that this injury was mediated in part by interleukin-18 (IL-18) and not by tumor necrosis factor-α (TNF-α).
When the injured myocytes were co-cultured with hMSCs, normal calcium signaling was preserved. The same protection was seen in transwell cultures, in which the myocytes and the hMSCs were separated by a permeable membrane that still allows soluble factors to pass. That result points to a paracrine signaling pathway — secreted factors — rather than a requirement that the two cell types touch or fuse.
LPS also caused the myocytes to release TNF-α. That release was blocked by hMSCs in both co-culture and transwell setups. Flow cytometry showed that hMSCs blocked the LPS- and IL-1β-dependent activation of the cardiac transcription factor NF-κB. Medium that had been conditioned by hMSCs (with no stem cells left in the dish) restored normal calcium signaling in myocytes that had already been damaged by LPS or IL-1β.
Taken together, the authors concluded that hMSCs can elicit protective and reparative effects on cardiac tissue by molecularly reprogramming the myocytes themselves, and they discussed this as a possible cellular mechanism relevant to heart failure. Those conclusions are about mechanisms in cultured cells.
Limitations
This was not a study in human patients. The work used neonatal mouse ventricular myocytes in culture and acute inflammatory or endotoxin stress in a dish. It does not report a patient count, ejection-fraction change, or clinical follow-up, and it cannot by itself predict whether a person with congestive heart failure or a prior heart attack will improve after MSC treatment. Results in the laboratory do not automatically translate to results in the clinic.
MSC injections aren’t FDA-approved for heart conditions in the US; Dream Body Clinic operates under COFEPRIS licensing in Mexico. Results vary.
For information on the clinic’s heart-failure protocol, see our congestive heart failure stem cell treatment page. Related reading: post heart attack stem cell treatment.
Citation: Rogers TB, Pati S, Gaa S, Riley D, Khakoo AY, Patel S, Wardlow RD, Frederick CA, Hall G, He LP, Lederer WJ. Mesenchymal stem cells stimulate protective genetic reprogramming of injured cardiac ventricular myocytes. J Mol Cell Cardiol. 2011 Feb;50(2):346–356. PMID 20837021. doi:10.1016/j.yjmcc.2010.09.001.
Call (888) 704-3977
For a Free Consultation
Or email us at info@dreambodyclinic.net
